|

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

RECRUITINGSponsored by Ferring Pharmaceuticals
Actively Recruiting
SponsorFerring Pharmaceuticals
Started2023-09-15
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations31 sites
View on ClinicalTrials.gov →

NCT06026332

Summary

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
* Signed and dated ICF.
* Age 18 years or older at day ICF is signed.

Exclusion Criteria:

* Currently enrolled in a clinical trial.
* Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
* Participant is pregnant or breastfeeding.

Conditions1

Bladder Cancer

Locations31 sites

Banner Health MD Anderson Cancer Center
Gilbert, Arizona, 85234
Mayo Clinic Arizona
Phoenix, Arizona, 85054
Arkansas Urology, North Little Rock
Little Rock, Arkansas, 72211
Urology Associates of Central California
Fresno, California, 93720
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.